A Phase 2 interventional study of Probiotic and Matching placebo in Infant, Newborn, Immunity and Immunisation, sponsored by South Australian Health and Medical Research Institute. Recruiting at 2 sites in Australia. Open to participants aged Up to 28 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by South Australian Health and Medical Research Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to investigate whether administering a probiotic (Infloran®) to infants who received antibiotics in the first 28 days of life can restore or enhance their immune response to routine vaccines.
Antibiotic use in the first weeks of life can lower the levels of beneficial gut bacteria, such as bifidobacteria, which play a key role in immune function. As a result, infants treated with antibiotics may produce fewer antibodies after routine vaccinations, leaving them less protected against infections.
The main questions this study aims to answer are:
Researchers will compare infants who receive Infloran® (a probiotic containing Bifidobacterium bifidum and Lactobacillus acidphilus) with those who receive a placebo (which contains the same excipients as Infloran® but does not contain any bacterial strains).
Participants will:
This study aims to recruit 360 infants to assess whether this probiotic treatment following antibiotic exposure improves the immunogenicity of vaccinations. The information from this study will improve our understanding of how probiotic intervention can support optimal immune responses to vaccination in early life. The findings could potentially influence public health strategies, offering a new way to support optimal vaccine responses in antibiotic-treated infants.
190 studies on the registry are indexed under Dysbiosis; 67 are open to participants now.
This study's planned enrollment of 360 is above the median of 60 across 134 interventional studies indexed under Dysbiosis.
Browse Dysbiosis studies →South Australian Health and Medical Research Institute is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
These participants will receive a probiotic, daily for fourteen days.
Drug: Probiotic
These participants will receive a placebo (contains the same excipients as the probiotic but no bacterial strains), daily for fourteen days.
Drug: Matching placebo
Probiotic capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. Probiotic Infloran® Hard capsules (Bifidobacterium bifidum \& Lactobacillus acidophilus) are a listed medicine on the Australian Register of Therapeutic Goods (ARTG). Infloran® has been previously used in infants including pre-term infants for other indications including supporting healthy digestion or improving digestive system flora. Infloran® is manufactured by Laboratorio Farmaceutico SIT S.r.l., Via Cavour 70 - 27035 Mede (PV) Italy.
Also known as: Infloran®
Placebo contains the same excipients as Infloran, it is also made from the same capsule, but it does not contain any bacterial strains. Placebo capsule contents will be dissolved in a small amount of breast milk, formula or sterile water (drinking water boiled, then cooled) and administered by the infant's parent/guardian to infants as an oral bolus dose. The placebo is manufactured by Syntro Health, 558-562 Swan St, Richmond, VIC 3121.
The Geometric Mean Concentrations (GMCs) of anticapsular antibodies against at least 11 serotypes included in the pneumococcal conjugate vaccine (PCV20) in serum collected at 6 months in the probiotics vs placebo group.
Time frame: 6 months
The GMCs for at least 11 serotypes included in pneumococcal conjugate vaccine (PCV20) as measured by serum assay at 12 months in the probiotic vs. placebo group.
Time frame: 12 months
The GMCs for other vaccine antigens (e.g. diphtheria, tetanus and pertussis toxoids, Haemophilus influenzae type b polyribosylribitol phosphate, Hepatitis B surface antigen) as measured by serum assays at 6 and 12 months in both arms.
Time frame: 12 months
Proportion of infants achieving seroprotective antibody levels (i.e. seroprotection) for pneumococcal antigens.
Time frame: 12 months
Activation-induced markers (AIM) assays will be performed to assess antigen-specific CD4 and CD8 T cell responses in probiotic vs. placebo groups.
Time frame: 12 months
Flow cytometry analysis of blood samples to compare immune cell frequencies and activation marker expression in probiotic vs. placebo groups.
Time frame: 12 months
Blood transcriptomics using RNA (ribonucleic acid) sequencing to measure gene expression responses to immunisation (i.e. which genes are turned on or off in blood) in probiotic vs. placebo groups.
Time frame: Before and after the participants' 6-week immunisations
Assessment of bacterial load (qPCR (quantitative Polymerase Chain Reaction) assay) and microbial composition of the stool microbiota using metagenomics (microbial DNA sequencing) in probiotic vs. placebo groups.
Time frame: 2 months
Correlative analysis of metagenomic, transcriptomic, and immunological datasets.
Time frame: 12 months
Assessment of whether probiotic supplementation influences the incidence and severity of respiratory infections during the first 12 months of life.
Time frame: 12 months
Plan to share: Yes — Non-identifiable individual participant data, from participants who give specific consent, may be made available long-term for use by future researchers from a recognised research institution whose proposed use of the data has been ethically reviewed and approved by an independent committee and who accept SAHMRI's conditions, under a collaborator agreement, for accessing: Individual participant data that underlie the results reported in our articles after deidentification (text, tables, figures and appendices) Study protocol, Statistical Analysis Plan, PICF Molecular data generated from this study (i.e. transcriptomic, epigenomic and metagenomic) will be labelled with a unique identification code and stored on an appropriate data repository (e.g. Gene Expression Omnibus, Sequence Read Archive) with demographic information (age and sex). No identifying participant information will be shared.
Supporting information: Study protocol, Informed consent form
Time frame: At the time of publication. Data will be available indefinitely.
Access criteria: Researchers from a recognised research institution can approach SAHMRI for access of data. The researcher will need to provide evidence that the proposed use of the data has been ethically reviewed and approved by an Institutional Review Board (IRB)/ Human Research Ethics Committee (HREC), and accept SAHMRI's conditions, under a collaborator agreement.
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Probiotic
South Australian Health and Medical Research Institute